Shree Aadinathay Namah
YASONS®
CHEMEX CARE LIMITED
CIN: U24304GJ2017PLC099511 (UAN: GJ01B0086285)
MANUFACTURING OF PERFUMES, DEODORANTS, DYESTUFF & TRADING OF ALL KINDS OF CHEMICALS
Registered Office: 4th floor, 412 Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad -380015.
Mobile No.9429000479 Ph. No. 079-26730258 email: yccl@yashchemex.com
web: www.yasonschemexcare.com

26th May 2025

To,
The Manager-Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051,
Maharashtra, India

Ref: **YASONS CHEMEX CARE LIMITED** **SYMBOL: YCCL** **SERIES: SM**

Sub: **OUTCOME OF BOARD MEETING, DISCLOSURE UNDER REGULATION 30 AND SUBMISSION OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY FOR THE HALF YEAR AND THE FINANCIAL YEAR ENDED 31ST MARCH 2025.**

Dear Sir,

In continuation of our letter dated 16th May 2025 and Pursuant to the Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended from time to time, we wish to inform that the Board of Directors of the Company at their meeting held today i.e., **Monday, 26th May 2025** have inter alia considered and approved the following matters:

1. Audited Annual Financial Results:

Approved the Audited Standalone and Consolidated Financial Results of the Company for the Half Year and the Financial Year ended 31st March 2025 along with Auditors' Report issued by the Statutory Auditors M/s H S K & CO LLP, Chartered Accountants (FRN: 117014W/W100685) which have been duly reviewed and recommended by the Audit Committee. In this regard, we are enclosing herewith:

(a) Auditors' Report on the Audited Standalone and Consolidated Financial Results of the Company for the Half Year and the Financial Year ended 31st March 2025 issued by the Statutory Auditors, M/s H S K & CO LLP, Chartered Accountants (FRN: 117014W/W100685).

(b) A copy of Audited Standalone and Consolidated Financial Results of the Company for the Half Year and the Financial Year ended 31st March 2025.

(c) Declaration in respect of Unmodified Opinion on the aforesaid Audited Standalone and Consolidated Financial Results and Statutory Auditors' Report.

We hereby declare that the Company's Statutory Auditors M/s H S K & CO LLP, Chartered Accountants (FRN: 117014W/W100685) have issued Audit Report with an Un-modified opinion on the Audited Standalone and Consolidated Financial Results of the Company for the Half Year and the Financial Year ended 31st March 2025.

The results will be available on the website of the Stock Exchange on the link www.nseindia.com and also on the website of the Company www.yasonschemexcare.com.

2. ***Appointment of M/s N. H. Desai & Co., Chartered Accountants as Internal Auditor of the Company for the Financial Year ending 31st March 2026:***

In terms of the recommendation from the Audit Committee, the Board of Directors of the Company has appointed M/s N. H. Desai & Co., Chartered Accountants. (FRN No. 161645W and M. No: 631230) as Internal Auditor of the Company to conduct the Internal Audit of the Company for the Financial Year ending 31st March 2026.

Further, the information required under the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024are as follows:

S. No	Details required	Appointment of Internal Auditor	
1	Reason for Change	Appointment of M/s N. H. Desai & Co., Chartered Accountants. (FRN No. 161645W and M. No: 631230) as Internal Auditor of the Company to conduct the Internal Audit of the Company for the Financial Year ending 31st March 2026.	
2	Date and Term of Appointment/~~Cessation~~	Date of Appointment: 26th May 2025 Term: To conduct the Internal Audit of the Company for the Financial Year ending 31st March 2026.	
3	Brief Profile	**Name of Auditor**	M/s N. H. Desai & Co., Chartered Accountants.
		Address	B 701, Titanium Business Park, Corporate Road, Ahmedabad, Gujarat - 380007 India.
		E-mail	canikundradesai@gmail.com
		Brief Profile	M/s N. H. Desai & Co., Chartered Accountants is a Chartered Accountancy firm founded in 2024. It provides comprehensive professional services which include Audit, Tax Advisory, Management Consultancy, Financial Management, Accounting Services, Secretarial Services, Corporate Advisory etc. to a large and wide variety of clients throughout India include leading private corporates & others and cover client like retail, hospitality, and information technology etc.
4	Disclosure of relationships between directors	Not related to any of the Directors of the Company.	

Shree Aadinathay Namah
YASONS®
CHEMEX CARE LIMITED
CIN: U24304GJ2017PLC099511 (UAN: GJ01B0086285)
MANUFACTURING OF PERFUMES, DEODORANTS, DYESTUFF & TRADING OF ALL KINDS OF CHEMICALS
Registered Office: 4th floor, 412 Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad -380015.
Mobile No.9429000479 Ph. No. 079-26730258 email: ycci@yashchemex.com
web: www.yasonschemexcare.com

3. ***Adoption of amended Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.***

This is to inform you that the Board of Directors of the Company has amended the "Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI)". The amended Code is enclosed with this disclosure for your records.

The said Code will be available on the website of the Company www.yasonschemexcare.com.

The Board meeting was commenced at 4:00 PM IST and concluded at 5:00 PM IST.

Kindly consider this and take on record as a requisite disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from to time.

Kindly take the same on your record.

Thanking you,

Yours faithfully,

For and on behalf of
Yasons Chemex Care Limited

PRITESH YASHWANTLAL SHAH

Digitally signed by PRITESH YASHWANTLAL SHAH
DN: c=IN, o=Personal, title=0155, 2.5.4.20=be1a5efcff398c3ccc7f4fc7c3cbf1fa32c9373 4be0d752cd940d837a041c6f5, postalCode=380015, st=Gujarat, serialNumber=5f2b385e9858e2ba9d0555fbb069310c65a15ecd62f0d12612c1231b4cbe89caa, cn=PRITESH YASHWANTLAL SHAH
Date: 2025.05.26 17:28:02 +05'30'

Pritesh Y. Shah
Managing Director
DIN: 00239665

Enclosed: A/a

H S K & CO LLP Chartered Accountants

410, 4th Floor, The Grand Mall, Opp. SBI Zonal Office, S. M. Road, Ambawadi, Ahmedabad-380015.
Phone : +91-79-40058744 / 40326773 • **E-mail :** htco.ca@gmail.com • ssshah.ca@gmail.com

Independent Auditor's Report on the Half Yearly and Year to Date Audited Standalone Financial Results of the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended

To,
The Board of Directors
Yasons Chemex Care Limited
Ahmedabad.

Report on Audit of the Standalone Financial Results

Opinion

We have audited the accompanying Standalone statement of **Yasons Chemex Care Limited** (the "Company"), for the half year and year ended on March 31, 2025 ("statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us this Standalone financial result:

i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS) and other accounting principles generally accepted in India, of the net profit and other comprehensive loss and other financial information for the half year ended March, 31 2025 as well as the year to date results for the period from April, 1 2024 to March, 31 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are

relevant to our audit of the standalone financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These half yearly standalone financial results as well as the year to date standalone financial results have been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive loss of the Company and other financial information in accordance with the applicable Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibilities also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of the appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial control that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial results that give a true and fair view and free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our Objectives are to obtain reasonable assurance about whether the Standalone Financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatement can arise from fraud or error and are considered material if,

individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists. We are required to draw attention in our auditor's report to the related disclosures in the standalone financial results, or if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transitions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial results.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The statement includes the results for the half year and year ended on March, 31 2025 being the balancing figure between the audited figures in respect of the full financial year ended March, 31 2025 and the published unaudited year-to-date figures up to the first half year of the current financial year, which were subjected to a limited review by us, as required under Listing Regulations.

For, H S K & Co LLP
Chartered Accountants
ICAI FRN: 117014W\W100685





CA. Sudhir Shah
Partner
Membership No. 115947
UDIN:- 25115947BMKZNP8141

Place : Ahmedabad,
Date : May 26,2025

Yasons Chemex Care Limited
(CIN: L24304GJ2017PLC099511)
4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad, Gujarat - 380015 India
E mail ID: cs@yasonschemexcare.com
Website: www.yasonschemexcare.com

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR AND THE FINANCIAL YEAR ENDED MARCH 31, 2025

	Particulars	(Rs. In Lakhs, except Earning per Share Value)				
		Half year Ended			Year Ended	
		31-03-2025	30-09-2024	31-03-2024	31-03-2025	31-03-2024
		Audited	Un-Audited	Audited	Audited	Audited
I	Revenue from operations	2,894.93	1,688.98	2,205.46	4,583.91	4,767.47
II	Other income	157.74	60.50	4.48	218.24	81.81
III	**Total income**	**3,052.67**	**1,749.48**	**2,209.95**	**4,802.15**	**4,849.28**
IV	**EXPENSES**					
(a)	Cost of materials consumed	287.62	1,059.25	1,273.96	1,346.87	3,199.46
(b)	Purchases of stock-in-trade	2,791.70	293.24	1,121.58	3,084.94	1,448.92
(c)	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(177.04)	132.94	(210.80)	(44.10)	(152.57)
(d)	Employee benefit expense	57.82	15.81	52.22	73.63	57.69
(e)	Finance costs	50.18	41.03	48.10	91.21	77.42
(f)	Depreciation and amortisation expense	4.44	4.40	5.11	8.84	10.22
(g)	Other expenses	48.60	1.44	42.08	50.04	58.76
	Total expenses	**3,063.32**	**1,548.11**	**2,332.25**	**4,611.42**	**4,699.91**
V	**Profit\(Loss) before tax**	**(10.65)**	**201.37**	**(122.30)**	**190.72**	**149.38**
VI	**Tax expense**					
(1)	Current tax	(16.66)	36.92	(25.46)	20.26	27.60
(2)	Deferred tax charge\(credit)	(1.23)	6.32	(6.99)	5.09	(7.63)
(3)	Tax In Respect of Earlier Years	4.20	-	5.31	4.20	5.31
	Total tax expense	**(13.69)**	**43.24**	**(27.14)**	**29.55**	**25.28**
VII	**Profit \(Loss) for the period**	**3.04**	**158.13**	**(95.15)**	**161.17**	**124.10**
VIII	**Other comprehensive income**					
(i)	Items that will not be reclassified to profit or loss	(0.93)	-	(1.62)	(0.93)	(1.62)
(ii)	Income tax relating to items that will not be reclassified to	0.23	-	0.41	0.23	0.41
IX	**Total comprehensive income for the period (VII+VIII)**	**2.34**	**158.13**	**(96.36)**	**160.47**	**122.89**
X	**Paid-Up Equity Share Capital of Face Value Rs.10/- Each**	1,930.39	1,930.39	1,930.39	1,930.39	1,930.39
XI	**Reserve Excluding Revaluation Reserves**				2,137.73	1,977.26
XII	**Basic & diluted earnings per share of face value of Rs.10 each fully paid up**					
(1)	Basic	0.01	0.82	-0.68	0.83	0.70
(2)	Diluted	0.01	0.82	-0.68	0.83	0.70

For, Yasons Chemex Care Limited

Pritesh Y. Shah
Managing Director
(DIN: 00239665)

Yasons Chemex Care Limited * Ahmedabad * INDIA

HSK & CO LLP * CHARTERED ACCOUNTANTS * AHMEDABAD

Place: Ahmedabad
Date: May 26,2025

Yasons Chemex Care Limited
(CIN: L24304GJ2017PLC099511)
4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad, Gujarat-380015
India
E mail ID: cs@yasonschemexcare.com
Website: www.yasonschemexcare.com

AUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT MARCH 31, 2025

(Rs. In Lakhs)

		Particulars	As at March 31, 2025	As at March 31, 2024
A		**ASSETS**	Audited	Audited
	1	**Non-current assets**		
		(a) Property, plant and equipment	36.96	43.19
		(b) Capital work-in-progress	-	-
		(c) Financial assets		
		(i) Non Current Investment	814.97	724.88
		(ii) Loans	-	-
		(iii) Other financial assets	23.20	42.35
		(d) Deferred Tax Assets	4.35	9.20
		(e) Non Current Assets	-	1.68
		Total non - current assets	**879.48**	**821.30**
	2	**Current assets**		
		(a) Inventories	1,259.97	1,075.44
		(b) Financial assets		
		(i) Investments	-	-
		(i) Trade receivables	2,718.89	2,609.24
		(ii) Cash and cash equivalents	10.01	15.47
		(iv) Other bank balances	-	-
		(v) Loans	-	-
		(iii) Bank Balance other than Cash and Cash Equivalents	105.08	-
		(iv) Other financial assets	-	-
		(c) Current Tax Assets (Net)	-	-
		(c) Other current assets	306.73	153.95
		Total current assets	**4,400.68**	**3,854.10**
		Total assets (1+2)	**5,280.16**	**4,675.40**
B		**EQUITY AND LIABILITIES**		
	1	**Equity**		
		(a) Equity share capital	1,930.39	1,930.39
		(b) Other equity	2,137.73	1,977.26
		Total equity	**4,068.12**	**3,907.65**
		LIABILITIES		
	2	**Non-current liabilities**		
		(a) Financial liabilities		
		Borrowings	-	42.08
		(b) Provisions	7.60	4.27
		Total non - current liabilities	**7.60**	**46.35**
	3	**Current liabilities**		
		(a) Financial liabilities		
		(i) Borrowings	608.94	433.11
		(ii) Trade payables	-	-
		- Total Outstanding dues of micro enterprises and small enterprises	-	-
		- Total Outstanding dues of creditors other than micro enterprises and small enterprises	369.87	226.03
		(ii) Other financial liabilities	-	-
		(b) Other current liabilities	211.01	42.60
		(c) Provisions	0.10	0.03
		(d) Current tax liabilities (Net)	14.52	19.63
		Total current liabilities	**1,204.44**	**721.40**
		Total equity and liabilities (1+2+3)	**5,280.16**	**4,675.40**

For, Yasons Chemex Care Limited

Pritesh Y. Shah
Managing Director
(DIN: 00239665)

Place: Ahmedabad
Date: May 26,2025

Yasons Chemex Care Limited * Ahmedabad * INDIA

H S K & CO LLP * CHARTERED ACCOUNTANTS * AHMEDABAD

Yasons Chemex Care Limited
(CIN: L24304GJ2017PLC099511)
4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad, Gujarat-380015 India
E mail ID: cs@yasonschemexcare.com
Website: www.yasonschemexcare.com

Audited Standalone Statement of Cash Flow for the Financial year ended March 31, 2025

(Rs. in Lakhs)

Particulars	Year Ended March 31, 2025	Year Ended March 31, 2024
	Audited	Audited
Cash flow from operating activities		
Profit Before tax	190.72	149.38
Adjustments for :		
Depreciation and amortisation expense	8.84	10.22
Provision for expected credit loss	(24.36)	25.00
Finance costs	91.21	77.42
Share of Profit from Investment In LLP	(90.09)	(66.19)
Interest income	(5.88)	(1.21)
Operating profit before working capital changes	**170.44**	**194.62**
Changes in operating assets and liabilities:		
(Increase)/Decrease in inventories	(184.54)	(269.98)
(Increase)/Decrease in trade receivables	(85.29)	(1,495.24)
(Increase)/Decrease in Other current financial assets , other current assets , Loans (Current + Non Current)	(237.04)	(105.49)
Increase/(Decrease) in trade payable	143.84	(66.16)
Increase/(Decrease) in other current financial liabitlies, other current liabitlies , Provisions (Current + Non Current)	170.87	44.81
Cash flow generated from operations	(21.72)	(1,697.45)
Direct taxes paid (net)	(29.56)	(59.04)
NET CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES	**(51.28)**	**(1,756.49)**
Cash flows from investing activities		
Purchase of property, plant and equipments (Net)	(2.61)	(1.69)
Interest Income	5.88	1.21
NET CASH FLOW FROM / (USED IN) IN INVESTING ACTIVITIES	**3.27**	**(0.48)**
Cash flows from financing activities		
Finance costs Payment	(91.21)	(77.42)
Proceeds from Issue of Equity Shares (Including Security Premium Reserve and net of Issue of Shares (IPO) Expenses)	-	1,712.63
Proceeds from Non-current and Current borrowings (Net)	133.75	128.79
NET CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES (C)	42.55	1,764.00
NET INCREASED / (DECREASED) IN CASH AND CASH EQUIVALENTS (A + B + C)	**(5.46)**	**7.03**
Cash and cash equivalents at the beginning of the year	15.47	8.44
Cash and cash equivalents at the end of the year	**10.01**	**15.47**

Notes:

(i). The above cash flow statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard - 7 Cash Flow Statements specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014.

(ii). Previous Period's / Year's figures have been re-grouped / Re-Classified where necessary to make it comparable with the current period.

For, Yasons Chemex Care Limited

Pritesh Y. Shah
Managing Director
(DIN: 00239665)

Place: Ahmedabad
Date: May 26,2025

Yasons Chemex Care Limited * INDIA * Ahmedabad *

H S K & CO LLP * AHMEDABAD * CHARTERED ACCOUNTANTS

Yasons Chemex Care Limited
(CIN: L24304GJ2017PLC099511)
4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad, Gujarat-380015 India
E mail ID: cs@yasonschemexcare.com
Website: www.yasonschemexcare.com

NOTES TO AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR AND THE FINANCIAL YEAR ENDED MARCH 31, 2025

1. The above Audited Standalone Financial Results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Company at their respective meetings held on Monday, May 26, 2025. The Statutory Auditor of the Company have carried out Statutory Audit of the above Audited Standalone Financial Results for the Half Year and the Financial Year ended March 31, 2025 as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The Statutory Auditors Report is annexed herewith. The Statutory Auditors have expressed an unmodified opinion.
2. The above Audited Standalone Financial Results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. The Company operates in a single segment and in line with Ind AS - 108 - "Operating Segments", the operation of the Company fall under only one Business which is considered to be the only reportable business segment.
4. The figures of second half of the year are the balancing figures between audited figures in respect of the full financial year and the published year to-date figures up to the first half year ended on September 30,2024 of the current financial year.
5. The figures for the previous period has been regrouped / re-arranged to make them comparable with the current period figures.
6. The Audited Standalone Financial Results are available on the Company's website and also on the website of the NSE where the shares of the Company are listed.

For, Yasons Chemex Care Limited

Yasons Chemex Care Limited INDIA Ahmedabad

Pritesh Y. Shah
Managing Director
(DIN: 00239665)

Place: Ahmedabad
Date: May 26,2025

H S K & CO LLP Chartered Accountants

410, 4th Floor, The Grand Mall, Opp. SBI Zonal Office, S. M. Road, Ambawadi, Ahmedabad-380015.
Phone : +91-79-40058744 / 40326773 • **E-mail :** htco.ca@gmail.com • ssshah.ca@gmail.com

Independent Auditor's Report on the Half Yearly and Year to Date Audited Consolidated Financial Results of the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended

To,
The Board of Directors
Yasons Chemex Care Limited
Ahmedabad.

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying consolidated financial results of **Yasons Chemex Care Limited** ('the Company') and its subsidiary for the half year and year ended March 31, 2025 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of report of other auditors on separate audited financial results of subsidiary, these consolidated financial results:

a. include the financial results of Rishit Polysurf LLP (a subsidiary)
b. are presented in accordance with the requirements of Regulation 33 of Listing Regulations in this regard; and
c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS) and other accounting principles generally accepted in India of the consolidated net profit and other comprehensive loss and other financial information for the half year ended March, 31 2025 as well as the year to date results for the period from April, 1 2024 to March, 31 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs'} specified under section 143(10) of the Companies Act, 2013 ('the Act'). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Company in accordance

H S K & CO LLP ★ CHARTERED ACCOUNTANTS ★ AHMEDABAD

with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Consolidated Financial Results

The Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of the Consolidated financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net consolidated profit/loss and other comprehensive loss and other financial information in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the Company and its subsidiary are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial results, the respective Board of Directors of the Company and of its subsidiary are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Company and its subsidiary are also responsible for overseeing the financial reporting process of the Company and its subsidiary.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material



misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions; misrepresentations, or the override of internal control.

- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as ageing concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether

H S K & CO LLP ★ CHARTERED ACCOUNTANTS ★ AHMEDABAD

the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the Company and its subsidiary to express an opinion on the consolidated financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the consolidated financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial results.

We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matter

a. We did not audit the financial statements/financial information of Rishit Polysurf LLP, in which the Company has invested 99%, whose financial statements reflect total assets of Rs. 1,608.54 lakhs as at March 31, 2025, total revenues of Rs. 3,269.22 lakhs and Net Profit after Tax of Rs. 91.00 lakhs and Total comprehensive income for the year then ended March 31,2025, as considered in the consolidated financial results. These financial statements/financial information have been audited by other

auditors whose reports have been furnished to us, and our opinion, in so far as it relates to the amounts and disclosures included in respect of this LLP, is based solely on the report of such other auditor.This Financial information is Material to the Group.

Our opinion on the consolidated financial results is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

For, H S K & Co LLP
Chartered Accountants
ICAI FRN: 117014W\W100685





CA. Sudhir Shah
Partner
Membership No. 115947
UDIN:- 25115947BMKZNQ7707

Place : Ahmedabad,
Date : May 26,2025

Yasons Chemex Care Limited
(CIN: L24304GJ2017PLC099511)
4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad, Gujarat - 380015 India
E mail ID: cs@yasonschemexcare.com
Website: www.yasonschemexcare.com

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR AND THE FINANCIAL YEAR ENDED MARCH 31, 2025

	Particulars	(Rs. In Lakhs, except Earning per Share Value)				
		Half Year Ended			Year Ended	
		31-03-2025	30-09-2024	31-03-2024	31-03-2025	31-03-2024
		Audited	Un-Audited	Audited	Audited	Audited
I	Revenue from operations	4,715.15	2,938.16	3,170.92	7,653.31	6,924.32
II	Other income	217.71	60.54	(11.38)	278.25	95.55
III	**Total income**	**4,932.86**	**2,998.70**	**3,159.54**	**7,931.56**	**7,019.87**
IV	**EXPENSES**					
(a)	Cost of materials consumed	2,127.20	2,195.89	2,171.50	4,323.09	5,195.99
(b)	Purchases of stock-in-trade	2,791.70	293.24	1,121.58	3,084.94	1,448.92
(c)	Changes in inventories of finished goods, stock-in-trade and	(177.04)	132.94	(210.80)	(44.10)	(152.57)
(d)	Employee benefit expense	47.03	28.86	76.14	75.89	81.61
(e)	Finance costs	75.15	68.36	83.54	143.51	132.91
(f)	Depreciation and amortisation expense	19.10	18.72	21.43	37.82	42.86
(g)	Other expenses	57.67	29.68	50.05	87.35	89.71
	Total expenses	**4,940.81**	**2,767.70**	**3,313.44**	**7,708.50**	**6,839.44**
V	**Profit\(Loss) before tax**	**(7.95)**	**231.00**	**(153.91)**	**223.06**	**180.43**
VI	**Tax expense**					
(1)	Current tax	14.77	36.92	4.93	51.69	57.99
(2)	Deferred tax charge\(credit)	(1.23)	6.32	(6.99)	5.09	(7.63)
(3)	Tax In Respect of Earlier Years	4.20	-	5.31	4.20	5.31
	Total tax expense	**17.74**	**43.24**	**3.25**	**60.98**	**55.67**
VII	**Profit\(Loss) for the period**	**(25.69)**	**187.76**	**(157.16)**	**162.08**	**124.76**
VIII	**Other comprehensive income**					
(i)	Items that will not be reclassified to profit or loss	(0.93)	-	(1.62)	(0.93)	(1.62)
(ii)	Income tax relating to items that will not be reclassified to	0.23	-	0.41	0.23	0.41
IX	**Total comprehensive income for the period (VII+VIII)**	**(26.39)**	**187.76**	**(158.37)**	**161.38**	**123.55**
X	**Paid-Up Equity Share Capital of Face Value Rs.10/- Each**	1,930.39	1,930.39	1,930.39	1,930.39	1,930.39
XI	**Reserve Excluding Revaluation Reserves**				2,137.72	1,977.26
XII	**Basic & diluted earnings per share of face value of Rs.10 each fully paid up**					
(1)	Basic	(0.24)	1.07	(1.06)	0.83	0.71
(2)	Diluted	(0.24)	1.07	(1.06)	0.83	0.71
XIII	**Net Profit attributable to:**					
	(a) Owner's of the company	(26.29)	187.46	(156.49)	161.17	124.09
	(b) Non-Controlling Interest	0.61	0.30	(0.67)	0.91	0.67
XIV	**Other Comprehensive Income attributable to:**					
	(a) Owner's of the company	(0.70)	-	(1.21)	(0.70)	- 1.21
	(b) Non-Controlling Interest	-	-	-	-	-
XV	**Total Comprehensive Income attributable to:**					
	(a) Owner's of the company	(26.99)	187.46	(157.70)	160.47	122.88
	(b) Non-Controlling Interest	0.61	0.30	(0.67)	0.91	0.67

For, Yasons Chemex Care Limited

Yasons Chemex Care Limited INDIA Ahmedabad

Pritesh Y. Shah
Managing Director
(DIN: 00239665)

H S K & CO LLP CHARTERED ACCOUNTANTS AHMEDABAD

Place: Ahmedabad
Date: May 26,2025

Yasons Chemex Care Limited
(CIN: L24304GJ2017PLC099511)
4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad, Gujarat-380015
India
E mail ID: cs@yasonschemexcare.com
Website: www.yasonschemexcare.com

AUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT MARCH 31, 2025

(Rs. In Lakhs)

		Particulars	As at March 31, 2025	As at March 31, 2024
A		ASSETS	Audited	Audited
	1	**Non-current assets**		
		(a) Property, plant and equipment	257.01	288.36
		(b) Capital work-in-progress	-	-
		(c) Goodwill	27.11	27.11
		(d) Financial assets		
		(i) Non Current Investment	-	-
		(ii) Loans	-	-
		(iii) Other financial assets	26.49	42.35
		(e) Deferred Tax Assets	4.35	9.20
		(f) Non Current Assets	-	1.68
		Total non - current assets	**314.96**	**368.70**
	2	**Current assets**		
		(a) Inventories	1,943.84	1,492.65
		(b) Financial assets		
		(i) Investments	-	-
		(i) Trade receivables	3,013.90	2,870.11
		(ii) Cash and cash equivalents	22.66	146.03
		(iv) Other bank balances	-	-
		(v) Loans	-	-
		(iii) Bank Balance other than Cash and Cash Equivalents	105.08	-
		(iv) Other financial assets	-	-
		(c) Current Tax Assets (Net)	-	-
		(c) Other current assets	532.43	581.99
		Total current assets	**5,617.91**	**5,090.78**
		Total assets (1+2)	**5,932.87**	**5,459.48**
B		**EQUITY AND LIABILITIES**		
	1	**Equity**		
		(a) Equity share capital	1,930.39	1,930.39
		(b) Other equity	2,137.72	1,977.26
		Equity attributable to equity holders of the company	**4,068.11**	**3,907.65**
		(c) Non-controlling interest	7.96	7.05
		Total Equity	**4,076.07**	**3,914.70**
		LIABILITIES		
	2	**Non-current liabilities**		
		(a) Financial liabilities		
		Borrowings	-	42.08
		(b) Provisions	7.60	4.27
		Total non - current liabilities	**7.60**	**46.35**
	3	**Current liabilities**		
		(a) Financial liabilities		
		(i) Borrowings	1,116.70	809.24
		(ii) Trade payables	-	-
		- Total Outstanding dues of micro enterprises and small enterprises	-	-
		- Total Outstanding dues of creditors other than micro enterprises and small enterprises	485.54	470.97
		(ii) Other financial liabilities	-	-
		(b) Other current liabilities	214.36	169.63
		(c) Provisions	0.10	0.13
		(d) Current tax liabilities (Net)	32.50	48.46
		Total current liabilities	**1,849.20**	**1,498.43**
		Total equity and liabilities (1+2+3)	**5,932.87**	**5,459.48**

For, Yasons Chemex Care Limited

Pritesh Y. Shah
Managing Director
(DIN: 00239665)

Place: Ahmedabad
Date: May 26,2025

Yasons Chemex Care Limited * INDIA * Ahmedabad *

H S K & CO. * CHARTERED ACCOUNTANTS * AHMEDABAD

Yasons Chemex Care Limited
(CIN: L24304GJ2017PLC099511)
4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad, Gujarat-380015 India
E mail ID: cs@yasonschemexcare.com
Website: www.yasonschemexcare.com

Audited Consolidated Statement of Cash Flow for the Financial year ended March 31, 2025

(Rs. in Lakhs)

Particulars	Year Ended March 31, 2025	Year Ended March 31, 2024
Cash flow from operating activities		
Profit Before tax	223.06	180.43
Adjustments for :		
Depreciation and amortisation expense	37.82	42.86
Provision for expected credit loss	(23.04)	25.00
Finance costs	143.51	132.91
Interest income	(5.88)	(1.21)
Operating profit before working capital changes	**375.47**	**379.99**
Changes in operating assets and liabilities:		
(Increase)/Decrease in inventories	(451.19)	(327.40)
(Increase)/Decrease in trade receivables	(122.12)	(1,184.18)
(Increase)/Decrease in Other current financial assets , other current assets , Loans (Current + Non Current)	(37.60)	(210.26)
Increase/(Decrease) in trade payable	14.57	(150.28)
Increase/(Decrease) in other current financial liabitlies, other current liabitlies , Provisions (Current + Non Current)	48.03	(64.67)
Cash flow generated from operations	(172.84)	(1,556.81)
Direct taxes paid (net)	(71.85)	(65.44)
NET CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES	**(244.69)**	**(1,622.25)**
Cash flows from investing activities		
Purchase of property, plant and equipments (Net)	(6.43)	(1.69)
Interest Income	5.88	1.21
NET CASH FLOW FROM / (USED IN) IN INVESTING ACTIVITIES	**(0.55)**	**(0.48)**
Cash flows from financing activities		
Finance Costs Payment	(143.51)	(132.91)
Proceeds from Issue of Equity Shares (Including Security Premium Reserve and net of Issue of Shares (IPO) Expenses)	-	1,712.63
Proceeds from Non-current and Current Borrowings (Net)	265.38	180.58
NET CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES (C)	121.87	1,760.31
NET INCREASED / (DECREASED) IN CASH AND CASH EQUIVALENTS (A + B + C)	**(123.37)**	**137.59**
Cash and cash equivalents at the beginning of the year	146.03	8.44
Cash and cash equivalents at the end of the year	**22.66**	**146.03**

Notes:

(i). The above cash flow statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard - 7 Cash Flow Statements specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014.

(ii). Previous Period's / Year's figures have been re-grouped / Re-Classified where necessary to make it comparable with the current period.

For, Yasons Chemex Care Limited

Yasons Chemex Care Limited * INDIA * Ahmedabad *

Pritesh Y. Shah
Managing Director
(DIN: 00239665)

Place: Ahmedabad
Date: May 26,2025

H S K & CO LLP * AHMEDABAD * CHARTERED ACCOUNTANTS

Yasons Chemex Care Limited
(CIN: L24304GJ2017PLC099511)
4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad, Gujarat-380015 India
E mail ID: cs@yasonschemexcare.com
Website: www.yasonschemexcare.com

NOTES TO AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR AND THE FINANCIAL YEAR ENDED MARCH 31, 2025

1. The above Audited Consolidated Financial Results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Company at their respective meetings held on Monday, May 26, 2025. The Statutory Auditor of the Company have carried out Statutory Audit of the above Audited Consolidated Financial Results for the Half Year and the Financial Year ended March 31, 2025 as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The Statutory Auditors Report is annexed herewith. The Statutory Auditors have expressed an unmodified opinion.
2. The above Audited Consolidated Financial Results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. The Audited Consolidated Financial Results for the Half Year and the Financial Year ended March 31, 2025 includes results of its Subsidiary entity : **Rishit Polysurf LLP**.
4. The Group operates in a single segment and in line with Ind AS - 108 - "Operating Segments", the operation of the Group fall under only one Business which is considered to be the only reportable business segment.
5. The figures of second half of the year are the balancing figures between audited figures in respect of the full financial year and the published year to-date figures up to the first half year ended on September 30,2024 of the current financial year.
6. The figures for the presented period has been regrouped / re-arranged to make them comparable with the current period figures.
7. The Audited Consolidated Financial Results are available on the Company's website and also on the website of the NSE where the shares of the Company are listed.

For, Yasons Chemex Care Limited

Yasons Chemex Care Limited * Ahmedabad * INDIA

Pritesh Y. Shah
Managing Director
(DIN: 00239665)

Place: Ahmedabad
Date: May 26,2025

Shree Aadinathay Namah

YASONS®

CHEMEX CARE LIMITED

CIN: U24304GJ2017PLC099511 (UAN: GJ01B0086285)

MANUFACTURING OF PERFUMES, DEODORANTS, DYESTUFF & TRADING OF ALL KINDS OF CHEMICALS

Registered Office: 4th floor, 412 Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad -380015.

Mobile No.9429000479 Ph. No. 079-26730258 email: yccl@yashchemex.com

web: www.yasonschemexcare.com

26th May 2025

To,
The Manager-Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051,
Maharashtra, India

Ref: YASONS CHEMEX CARE LIMITED SYMBOL: YCCL SERIES: SM

Sub.: DECLARATION OF UN-MODIFIED OPINION WITH AUDIT REPORT ON AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR HALF YEAR AND THE FINANCIAL YEAR ENDED 31ST MARCH 2025.

Dear Sir,

This is in reference to the Regulation 33 (3)(d) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended by the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2016 vide Notification No. SEBI/ LAD-NRO/ GN/ 2016-17/ 001 dated 25/05/2016.

We hereby confirm and declare that the Company's Statutory Auditors M/s H S K & CO LLP, Chartered Accountants (FRN: 117014W/W100685) have issued Audit Report with an Un-modified opinion on the Audited Standalone and Consolidated Financial Results for the Half Year and the financial year ended 31st March 2025.

Kindly take the above on records.

Thank you,

For and on behalf of
Yasons Chemex Care Limited

Yasons Chemex Care Limited INDIA Ahmedabad

Pritesh Y. Shah
Managing Director
DIN: 00239665

H S K & CO LLP Chartered Accountants

307, 3rd Floor, The Grand Mall, Opp. SBI Zonal Office, S. M. Road, Ambawadi, Ahmedabad-380015.
Phone : +91-79-40058744 / 40326773 • E-mail : htco.ca@gmail.com • ssshah.ca@gmail.com

To,
Audit Committee of
Yasons Chemex Care Limited
Ahmedabad

Sir,

Sub: Auditors Certificate on Utilization of Funds Raised from Initial Public Offer of Yasons Chemex Care Limited ("the Company").

Ref: Pursuant to Regulation 32 (1) of the SEBI (Listing Obligation and Disclosure requirement) Regulations, 2015 read with NSE Circular Ref. No: NSE/CML/2024/23 dated 05th September 2024.

With reference to the above captioned subject, we hereby certify that **Yasons Chemex Care Limited** ("the Company") has raised in total **INR 2056.80 Lakhs** from the Issue of Equity Shares through Initial Public Offer.

Further, the details of utilization of proceeds raised from Initial Public Offer for the purpose of the objects as stated in Offer Document (Prospectus) of the Company dated 17th July 2023 are as under:


Amount (in Lakhs)

Sr. No.	Object as disclosed in the Offer Document	Amount disclosed in the Offer Document	Actual Utilised Amount	Unutilised Amount	Remarks
1	Issue related Exp as per Prospectus	339.37	339.37	Nil	Nil
1	Meeting incremental working capital requirements	1230.63	1230.63	Nil	Nil
2	General Corporate Purpose	486.80	485.44	1.36	Nil
		2056.80	**2055.44**	**1.36**	**Nil**

H S K & CO LLP ★ AHMEDABAD ★ CHARTERED ACCOUNTANTS

We further confirm that there has been no deviation/variation in utilization, except mentioned above, of the issue proceeds raised from Initial Public Offer of the Company from those mentioned in the Offer Document of the Company.

For M/s H S K & CO LLP
Chartered Accountants
(FRN: 117014W/W100685).





CA. Sudhir S Shah
(Partner)
M. No. 115947
UDIN: 25115947BMKZNK7867

Place: Ahmedabad
Date: May 24, 2025

CODE OF PRACTICES & PROCEDURES FOR THE FAIR DISCLOSURE OF UNPUBLISHED PRICE SENSITIVE INFORMATION

(Modified in the Board Meeting dated 26th May 2025)

1. INTRODUCTION

This Code has been framed in pursuance to the regulation contained in sub regulation (1) of Regulation 8 of SEBI (Prohibition of Insider Trading) Regulations, 2015 and the purpose of this code is to ensure timely and adequate disclosure of Unpublished Price Sensitive Information.

2. CODE OF FAIR DISCLOSURE

Yasons Chemex Care Limited ("YCCL") has formulated this Code called "YCCL" Code of Practices and Procedures for Fair Disclosures of Unpublished Price Sensitive Information to ensure timely and adequate disclosure of unpublished price sensitive information which would impact the price of the Company's securities and to maintain the uniformity, transparency and fairness in dealing with all stakeholders and in ensuring adherence to applicable laws and regulations. Further, the Company endeavours to preserve the confidentiality of unpublished price sensitive information and to prevent misuse of such information.

3. DEFINITIONS

"**Board of Directors**" or "**Board**" means the Board of Directors of YCCL, as constituted from time to time.

"**Chief Investor Relation Officer**" means the Compliance Officer of the Company, who shall be responsible for dissemination of information and disclosure of unpublished price sensitive information."

"**Compliance Officer**" for the purpose of these regulations means the Company Secretary of the Company. In absence of the Company Secretary the Board of Directors may authorize such other Senior Officer of the Company who is financially literate and is capable of appreciating requirements for legal and regulatory compliance under these regulations and who shall be responsible for compliance of policies, procedures, maintenance of records, monitoring adherence to the rules for the preservation of unpublished price sensitive information, monitoring of trades and the implementation of the codes specified in these regulations under the overall supervision of the board of directors of the listed company or the head of an organization, as the case may be.

"**Unpublished Price Sensitive Information**" **or** "**UPSI**" means any information, relating to a Company or its securities, directly or indirectly, that is not generally available which upon becoming generally available, is likely to materially affect the price of the securities and shall, ordinarily including but not restricted to, information relating to the following:

(i) financial results;
(ii) dividends;
(iii) change in capital structure;
(iv) mergers, de-mergers, acquisitions, delistings, disposals and expansion of business, [award or termination of order/contracts not in the normal course of business] w.e.f. June 10, 2025 and such other transactions; and
(v) Changes in key managerial personnel, [other than due to superannuation or end of term, and resignation of a Statutory Auditor or Secretarial Auditor]. w.e.f. June 10, 2025
(vi) Change in rating(s), other than ESG rating(s).

(vii) fund raising proposed to be undertaken
(viii) agreements, by whatever name called, which may impact the management or control of the company
(ix) fraud or defaults by the company, its promoter, director, key managerial personnel, or subsidiary or arrest of key managerial personnel, promoter or director of the company, whether occurred within India or abroad
(x) resolution plan/ restructuring or one-time settlement in relation to loans/borrowings from banks/financial institutions
(xi) admission of winding-up petition filed by any party /creditors and admission of application by the Tribunal filed by the corporate applicant or financial creditors for initiation of corporate insolvency resolution process against the company as a corporate debtor, approval of resolution plan or rejection thereof under the Insolvency and Bankruptcy Code, 2016
(xii) initiation of forensic audit, by whatever name called, by the company or any other entity for detecting mis-statement in financials, misappropriation/ siphoning or diversion of funds and receipt of final forensic audit report;
(xiii) action(s) initiated or orders passed within India or abroad, by any regulatory, statutory, enforcement authority or judicial body against the company or its directors, key managerial personnel, promoter or subsidiary, in relation to the company
(xiv) outcome of any litigation(s) or dispute(s) which may have an impact on the company
(xv) giving of guarantees or indemnity or becoming a surety, by whatever named called, for any third party, by the company not in the normal course of business
(xvi) granting, withdrawal, surrender, cancellation or suspension of key licenses or regulatory approvals] w.e.f. June 10, 2025

Words not defined in this Fair Disclosure Code shall have the meaning ascribed to them in the Regulations.

4. PRINCIPLES OF DISCLOSURE

The Company will adhere to the following principles so as to ensure fair disclosure of events, occurrence and Unpublished Price Sensitive Information that could impact the price of its securities in the market:

I. The Company will make prompt public disclosure of unpublished price sensitive information that would impact price discovery no sooner than credible and concrete information comes into being in order to make such information generally available.

II. The Company will make uniform and universal dissemination of unpublished price sensitive information to avoid selective disclosure.

III. The Chief Investor Relation Officer of the Company shall deal with dissemination of information and disclosure of unpublished price sensitive information.

IV. The Company will make prompt dissemination of unpublished price sensitive that gets disclosed selectively, inadvertently or otherwise to make such information generally available.

V. The Company will provide appropriate and fair responses to queries on news reports and requests for verification of market rumors by regulating authorities.

VI. The Company will ensure that information, if shared, with analysts and research personnel are not unpublished price sensitive information.

VII. The Company will develop the best practices to make transcripts or records of proceedings of meetings with analysts and other investor relations conferences on the official website to ensure official confirmation and documentation of disclosures made.

VIII. The Company will handle all unpublished price sensitive information on a need-to-know basis.

5. SHARING OF UPSI FOR LEGITIMATE PURPOSE

The unpublished price sensitive information shall be shared by any person(s) authorized by the Board of Directors or Chief Investor Relation Officer of the Company in this behalf, only in furtherance of legitimate purpose(s), on a need-to-know basis, which shall include the following;

(i) Sharing such information in the ordinary course of business by any Insider, Designated Person, or by any Authorized person with existing or proposed partners, collaborators, lenders, customers, suppliers, merchant bankers, legal advisors, auditors, insolvency professionals or other advisors or consultants.

(ii) Where such communication is in furtherance of performance of duty (ies) or for discharge of legal obligation(s) or for any other genuine or reasonable purpose as may be determined by Chief Investor Relation Officer.

(iii) Sharing of such information for any other purpose as may be prescribed under the Securities Regulations or Company Law or any other law for the time being in force, in this behalf, as may be amended from time to time.

Provided that such sharing has not been carried out to evade or circumvent the prohibitions of SEBI (Prohibition of Insider Trading) Regulations, 2015.

6. NOTICE TO RECIPIENT OF UPSI

Any person in receipt of unpublished price sensitive information pursuant to a "legitimate purpose" shall be considered an "insider" for purposes of this Code and due notice shall be given to such persons;

(i) To make such person aware that the information shared is or would be UPSI.

(ii) To instruct such person to maintain confidentiality of such UPSI in compliance with these regulations.

(iii) To make such person aware of the duties and responsibilities attached to the receipt of such UPSI and the liability attached to misuse or unwarranted use of such UPSI.

7. MAINTENANCE OF DIGITAL DATABASE

The Company shall maintain a structured digital database containing the names of such persons or entities as the case may be with whom information is shared for legitimate purposes which shall contain the following information;

(i) Name of such recipient of UPSI;
(ii) Name of the Organization or entity to whom the recipient represents
(iii) Permanent Account Number (PAN) or any other identifier authorized by law, if PAN is not available

Such databases shall be maintained with an adequate and effective system of internal controls and checks such as time stamping and audit trials to ensure non-tampering of such database.

[Such entry of information, not emanating from within the organisation, in structured digital database may be done not later than 2 calendar days from the receipt of such information.] w.e.f. June 10, 2025

Board of Directors or Chief Investor Relation Officer of the Company who are required to handle unpublished price sensitive information shall ensure that the structured digital database is preserved for a period of not less than eight years after completion of the relevant transactions and in the event of receipt of any information from the Board regarding any investigation or enforcement proceedings, the relevant information in the structured digital database shall be preserved till the completion of such proceedings.

8. SILENT PERIOD

The silent period shall commence 15 days prior to the date of the Board meeting in which financial results are considered till the time of disclosure of the financial results are made public.

During the silent period the company will completely refrain from the analysts/ investors meets. In case of exigencies or good opportunity if the Investors intend to interact with Company's top executives while avoiding disclosure of UPSI, they can discuss the historical data which is available in public domain and general future prospects of the Company.

9. AMENDMENTS

The Board shall have the power to amend any of the provisions of the Code of Fair Disclosure, substitute any of the provisions with a new provision or replace this Fair Disclosure Code entirely with a new Code of Fair Disclosure.

****